Skip to Content


In the US, Mepolizumab (mepolizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Asthma, Asthma - Maintenance and Eosinophilic Granulomatosis with Polyangiitis.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Therapeutic Categories


Interleukin Inhibitor

Chemical Name

Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563γ1-chain), disulfide with human-mouse monoclonal SB-240563κ-chain, dimer (WHO)

Foreign Names

  • Mepolizumabum (Latin)
  • Mepolizumab (German)
  • Mépolizumab (French)
  • Mepolizumab (Spanish)

Generic Names

  • Mepolizumab (OS: USAN, JAN)
  • SB-240563 (IS)
  • UNII-90Z2UF0E52 (IS)

Brand Names

  • Nucala
    GlaxoSmithKline, Switzerland; GlaxoSmithKline, Germany; GlaxoSmithKline, United States; GlaxoSmithKline UK, United Kingdom


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.